• DOI:10.1200/JCO.2013.31.15_SUPPL.TPS3108
Corpus ID: 74222414

A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies.

@article{Kohrt2013API,
  title={A phase Ib, open-label, multicenter study of urelumab (BMS-663513) in combination with rituximab in subjects with relapsed/refractory B-cell malignancies.},
  author={H. Kohrt and J. Godwin and I. Lossos and M. Williams and J. Timmerman and B. Link and S. Goldberg and A. McGirr and J. Kurland and J. Wigginton and L. Cohen and R. Levy},
  journal={Journal of Clinical Oncology},
  year={2013},
  volume={31}
}

H. Kohrt, J. Godwin, +9 authors R. Levy

Published 2013

Medicine

Journal of Clinical Oncology

TPS3108 Background: CD137 (4-1BB) is a costimulatory molecule that belongs to the TNF superfamily. It is upregulated on activated lymphocytes, NK cells and dendritic cells and plays an important role in the potentiation of antigen-specific immune responses as well as in antibody-dependent cell-mediated cytotoxicity (ADCC). Urelumab is an agonistic antibody targeting the CD137 receptor. Preclinical evidence has shown that there is modulation of CD137 expression on NK cells after exposure to… CONTINUE READING

View via Publisher

Save to Library

Create Alert

Cite

Launch Research Feed